IFM Therapeutics (2)

Executive Summary

IFM Therapeutics is a private, clinical-stage biopharmaceutical company pioneering novel therapies that modulate the innate immune system to treat oncology and inflammatory diseases. Founded in 2015 and headquartered in the United States, the company leverages a dual-platform approach combining biologics and small molecules. IFM's pipeline targets key innate immune pathways, including STING, NLRP3, and other pattern recognition receptors, with the goal of generating first-in-class or best-in-class therapeutics. The company has completed two discrete financing rounds to support its R&D programs, and its most advanced candidates have entered clinical trials. By focusing on the under-explored innate immune system, IFM aims to address significant unmet medical needs across multiple indications.

Upcoming Catalysts (preview)

• Q4 2026Phase 1/2 data readout for IFM-001 (STING agonist) in solid tumors40% success
• Q3 2026Initiation of Phase 2 trial for IFM-002 (NLRP3 inhibitor) in inflammatory disease65% success
• Q1 2027Potential partnership or licensing deal for IFM-003 (cGAS inhibitor)50% success